Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Celldex Therapeutics Inc (NASDAQ: CLDX) closed at $26.84 in the last session, down -0.63% from day before closing price of $27.01. In other words, the price has decreased by -$0.63 from its previous closing price. On the day, 0.83 million shares were traded. CLDX stock price reached its highest trading level at $28.1499 during the session, while it also had its lowest trading level at $26.77.
Ratios:
We take a closer look at CLDX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 24.27 and its Current Ratio is at 24.27. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on October 07, 2024, initiated with a Buy rating and assigned the stock a target price of $70.
On September 30, 2024, Goldman started tracking the stock assigning a Neutral rating and target price of $45.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 11 ’24 when Marucci Anthony S bought 11,500 shares for $26.82 per share. The transaction valued at 308,430 led to the insider holds 40,284 shares of the business.
Martin Samuel Bates sold 17,172 shares of CLDX for $608,315 on Jun 14 ’24. The SVP AND CFO now owns 28,125 shares after completing the transaction at $35.42 per share. On Jun 14 ’24, another insider, Crowley Elizabeth, who serves as the SR. VP & CPDO of the company, sold 30,000 shares for $34.87 each. As a result, the insider received 1,045,962 and left with 9,074 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLDX now has a Market Capitalization of 1793285120 and an Enterprise Value of 1027767296. For the stock, the TTM Price-to-Sale (P/S) ratio is 178.42 while its Price-to-Book (P/B) ratio in mrq is 2.27. Its current Enterprise Value per Revenue stands at 103.024 whereas that against EBITDA is -6.008.
Stock Price History:
Over the past 52 weeks, CLDX has reached a high of $53.18, while it has fallen to a 52-week low of $24.43. The 50-Day Moving Average of the stock is -17.79%, while the 200-Day Moving Average is calculated to be -27.88%.
Shares Statistics:
According to the various share statistics, CLDX traded on average about 1.08M shares per day over the past 3-months and 1201540 shares per day over the past 10 days. A total of 66.34M shares are outstanding, with a floating share count of 64.15M. Insiders hold about 3.31% of the company’s shares, while institutions hold 106.29% stake in the company. Shares short for CLDX as of 1730332800 were 8239830 with a Short Ratio of 7.60, compared to 1727654400 on 8306171. Therefore, it implies a Short% of Shares Outstanding of 8239830 and a Short% of Float of 14.37.
